UBS Reiterates Buy Rating on Eli Lilly (LLY)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. META

Go back to UBS Reiterates Buy Rating on Eli Lilly (LLY)

Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage

April 21, 2026 1:33 PM EDT

Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,327.00 price target on Eli Lilly (NYSE: LLY).

The analyst comments "The broadening of Medicare coverage for the GLP-1 medications for obesity is a key driver of US market growth for LLYs Zepbound as weve previously discussed (see HERE and HERE). Recent commentary from UNH and CVS (see below; both stocks covered by Erin Wright) have raised some questions about the path to broader coverage via the CMS BALANCE program in 2027 following a 2026 bridge program (which begins July 1), which has... More